BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peacock A, Keogh A, Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Current Opinion in Pulmonary Medicine 2010;16:S1-9. [DOI: 10.1097/01.mcp.0000370205.22885.98] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Bai Y, Sun L, Hu S, Wei Y. Combination Therapy in Pulmonary Arterial Hypertension: A Meta-Analysis. Cardiology 2011;120:157-65. [DOI: 10.1159/000334431] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
2 Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, Mcgoon MD. Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension. Chest 2013;144:1521-9. [DOI: 10.1378/chest.12-3023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
3 Zhu B, Wang L, Sun L, Cao R. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis. J Cardiovasc Pharmacol 2012;60:342-6. [PMID: 22691882 DOI: 10.1097/FJC.0b013e318262a793] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
4 Frantz RP, Mcdevitt S, Walker S. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. The Journal of Heart and Lung Transplantation 2012;31:811-6. [DOI: 10.1016/j.healun.2012.04.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
5 Hemnes AR, Pugh ME, Newman AL, Robbins IM, Tolle J, Austin ED, Newman JH. End tidal CO(2) tension: pulmonary arterial hypertension vs pulmonary venous hypertension and response to treatment. Chest 2011;140:1267-73. [PMID: 21622547 DOI: 10.1378/chest.11-0155] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
6 Jose A, King CS, Shlobin OA, Kiernan JM, Cossa NA, Brown AW, Nathan SD. Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension. Chest 2017;152:980-9. [PMID: 28527879 DOI: 10.1016/j.chest.2017.05.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Amin A, Mohamadifar A, Keshmiri MS, Ghadrdoost B, Taghavi S, Naderi N. A simple hemodynamic parameter to predict clinical worsening in pulmonary arterial hypertension. J Crit Care 2017;38:324-7. [PMID: 27988069 DOI: 10.1016/j.jcrc.2016.12.002] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Radke RM, Diller G, Baumgartner H. The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease. Expert Review of Cardiovascular Therapy 2014;11:919-31. [DOI: 10.1586/14779072.2013.811966] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wu Y, O'Callaghan DS, Humbert M. An update on medical therapy for pulmonary arterial hypertension. Curr Hypertens Rep 2013;15:614-22. [PMID: 24122306 DOI: 10.1007/s11906-013-0394-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
10 Zuk M, Migdal A, Jagiellowicz-Kowalska D, Mazurkiewicz K, Sadel-Wieczorek A, Brzezinska-Rajszys G. Six-Minute Walk Test in Evaluation of Children with Pulmonary Arterial Hypertension. Pediatr Cardiol 2017;38:754-61. [PMID: 28239753 DOI: 10.1007/s00246-017-1575-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Saglam M, Vardar-Yagli N, Calik-Kutukcu E, Arikan H, Savci S, Inal-Ince D, Akdogan A, Tokgozoglu L. Functional exercise capacity, physical activity, and respiratory and peripheral muscle strength in pulmonary hypertension according to disease severity. J Phys Ther Sci 2015;27:1309-12. [PMID: 26157207 DOI: 10.1589/jpts.27.1309] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
12 Woods PR, Taylor BJ, Frantz RP, Johnson BD. A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension. Am J Cardiol 2012;109:1066-72. [PMID: 22245407 DOI: 10.1016/j.amjcard.2011.11.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
13 Fox BD, Shtraichman O, Langleben D, Shimony A, Kramer MR. Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. Can J Cardiol 2016;32:1520-30. [PMID: 27378592 DOI: 10.1016/j.cjca.2016.03.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
14 Fox BD, Langleben D, Hirsch A, Boutet K, Shimony A. Step climbing capacity in patients with pulmonary hypertension. Clin Res Cardiol 2013;102:51-61. [DOI: 10.1007/s00392-012-0495-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
15 Selej M, Romero AJ, Channick RN, Clozel M. Development of macitentan for the treatment of pulmonary arterial hypertension. Ann N Y Acad Sci 2015;1358:68-81. [PMID: 26291180 DOI: 10.1111/nyas.12856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 McGlinchey N, Peacock AJ. Endpoints in PAH clinical trials in the era of combination therapy: how do we decide whether something is working without going bankrupt? Drug Discov Today 2014;19:1236-40. [PMID: 24814434 DOI: 10.1016/j.drudis.2014.04.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
17 Ploegstra MJ, Arjaans S, Zijlstra WMH, Douwes JM, Vissia-Kazemier TR, Roofthooft MTR, Hillege HL, Berger RMF. Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension. Chest 2015;148:655-66. [PMID: 25741884 DOI: 10.1378/chest.14-3066] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
18 Wang RC, Jiang FM, Zheng QL, Li CT, Peng XY, He CY, Luo J, Liang ZA. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Respir Med 2014;108:531-7. [PMID: 24462476 DOI: 10.1016/j.rmed.2014.01.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]